Watchman™ Ewolution prospective registry - 3 months results & clinical impact
Sponsored by Boston Scientific
Summary: Interview with Prof. Martin W. Bergmann on the EWOLUTION registry the largest prospective real-life LAAC registry with over 1,000 patients studied. The EWOLUTION registry is a multicenter study designed to obtain clinical data on procedural success, complication rates, incidence of stroke, bleeding and long-term patient outcomes.
EWOLUTION Key Results & Findings1
HIGH RISK POPULATION
Patients not eligible for OAC
3 MONTHS RESULTS
No or minimal leak at first follow-up
- Device or procedure related serious adverse events (SAE) rates at 92 days were similar if patients were treated with warfarin or DAPT (2.6% vs. 4.8%, respectively).
- Bleeding SAE rates were also similar if warfarin or DAPT was used post-implantation (4.8% vs. 3.6%, respectively).
- Registry on WATCHMAN™ Outcomes in Real-Life Utilization
1Bergmann M. W. et al. presented at EuroPCR 2016, Paris May 17th-20th
Boston Scientific Disclaimer
All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. SH-402401-AA - JUNE 2016
Prof. Martin W. Bergmann